CTOs on the Move

Code42

www.code42.com

 
Code42, the leader in endpoint data protection and recovery, securely and continuously backs up end-user data for more than 47,000 organizations worldwide, including the most recognized brands in business and education. Our cloud solutions enable IT and security teams to centrally view, protect, and manage end-user data as a critical corporate asset. Code42 limits risk by enabling IT to monitor data movement and use, meet data privacy regulations and recover rapidly from data loss—no matter the cause. Code42 employs a diverse group of talented, hungry minds in engineering, marketing, sales and customer service, and is headquartered in the Washington ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.code42.com
  • 100 Washington Avenue South Suite 2000
    Minneapolis, MN USA 55401
  • Phone: 612.333.4242

Executives

Name Title Contact Details
Jason Greenwood
 Chief Revenue Officer (CRO) Profile
Clea Ostendorf
 Field CISO Profile
Matt Jackson
 Sr Director, Security Operations Profile
Tommy Todd
 Vice President of Security Profile
Todd Thorsen
 Director Information Security, Risk Management and Compliance Profile

Similar Companies

Innovative Cyber Solutions

Innovative Cyber Solutions is a Miami, FL-based company in the Software and Internet sector.

Network Executive Software (NetEx)

Network Executive Software, Inc. (NetEx) is a Maple Grove, MN-based company in the Software and Internet sector.

Team Cymru

Our goal is to save and improve human lives. We do this by helping organizations identify and eradicate problems in their networks.

Apature Cable Products

Apature Cable Products is a Bunnell, FL-based company in the Software and Internet sector.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.